EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults

Yan Wu, Xiao Long iD, Nanze Yu, Jin Chen, Jianyun Lu, Lina Tan, Wei Lai, Li Li, Sufan Wu, Liming Wu, Jiaming Sun, Hongsen Bi und 9 weitere

Aesthetic Surgery Journal · 18.05.2026 · 46 (6) · 672-679

DOI: 10.1093/asj/sjag042 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 14.02.2026. Verfasst von Yan Wu und 20 weiteren Autor:innen. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Neuromuscular Agents, Cosmetic Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing Claruvis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.

Objectives

To evaluate the efficacy, safety, and immunogenicity of YY001, a recombinant botulinum toxin type A (Chongqing Claruvis Pharmaceutical Co., Ltd., Chongqing, China), in the treatment of moderate-to-severe glabellar lines.

Methods

In this multicenter, randomized, double-blind, vehicle- and active-controlled Phase III trial, 529 adults aged 18-65 with moderate to severe glabellar lines were randomized 4:2:1 to receive a single 20 U injection of YY001, Botox®(Allergan Pharmaceuticals Ireland, Westport, Ireland), or vehicle. The primary endpoint was composite response rate (CRR) at Week 4, defined as a ≥2-grade improvement of glabellar line severity assessed by both investigator and participant. Secondary endpoints included onset time, duration, satisfaction, and safety.

Results

YY001 achieved a CRR of 86.7% at Week 4, significantly outperforming Botox® (66.7%, P < .0001) and vehicle (1.3%, P < .0001). It showed faster onset, longer median duration (97 days), and high participant satisfaction. Adverse events were mild and comparable across groups. Only one case of anti-drug antibody was observed; no neutralizing antibodies were detected. A 12-week follow-up and ethnically homogenous population may limit generalizability.

Conclusions

YY001 demonstrated strong efficacy and a favorable safety profile than Botox®. Longer-term and multicenter studies are needed to assess durability, immunogenicity, and applicability across broader populations. Level of Evidence: 1 (Therapeutic) For image description, please refer to the figure legend and surrounding text.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ASkin AgingNeuromuscular AgentsCosmetic TechniquesHumansDouble-Blind MethodAdultMiddle AgedFemaleMaleTreatment OutcomeYoung AdultRecombinant ProteinsAdolescentAgedChinaForeheadEast Asian People

Substanzen

Botulinum Toxins, Type ARecombinant ProteinsNeuromuscular Agents

Autor:innen und Institutionen

ORCID-Profile: Xiao Long

Förderung

  • Chongqing Claruvis

Zitieren

APA

Wu, Y., Long, X., Yu, N., Chen, J., Lu, J., Tan, L., Lai, W., Li, L., Wu, S., Wu, L., Sun, J., Bi, H., Geng, S., Wang, H., Luo, S., Hu, Z., Yang, J., Wang, B., Yang, W., …, & Sun, X. (2026). Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults. Aesthetic Surgery Journal, 46(6), 672-679. https://doi.org/10.1093/asj/sjag042

Vancouver

Wu Y, Long X, Yu N, Chen J, Lu J, Tan L, et al. Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults. Aesthetic Surgery Journal. 2026;46(6):672-679. doi:10.1093/asj/sjag042

BibTeX
@article{Wu2026,
  author = {Wu, Yan and Long, Xiao and Yu, Nanze and Chen, Jin and Lu, Jianyun and Tan, Lina and Lai, Wei and Li, Li and Wu, Sufan and Wu, Liming and Sun, Jiaming and Bi, Hongsen and Geng, Songmei and Wang, Huiping and Luo, Shengkang and Hu, Zhiqi and Yang, Jianmin and Wang, Baoxi and Yang, Wu and Sun, Xiaoli and Sun, Xiaoyun},
  title = {Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults},
  journal = {Aesthetic Surgery Journal},
  year = {2026},
  volume = {46},
  number = {6},
  pages = {672--679},
  doi = {10.1093/asj/sjag042}
}
Kostenlos starten →